Abstract
Abstract Can the design of experiments in a major industry be based on unsound principles? A key principle in experimental design is to control all variables except for the ones being studied. But the pharmaceutical industry tests the toxicity of potential new drugs by using genetically heterogeneous rats and mice, even though these can vary hugely in their responses. This reduces the power of their experiments. Michael Festing asks why basic design principles are being ignored; can this be a contributing factor to the high cost of drug development?
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
